Verification note: PBS listings, TGA scheduling, and pricing change frequently. PBS status and co-payments on this page were re-checked in September 2026 against pbs.gov.au and health.gov.au. Always verify current status at pbs.gov.au and tga.gov.au before making treatment decisions.
Short answer: Ozempic yes, Mounjaro no.
Ozempic (semaglutide) is PBS-listed in Australia, but only for type 2 diabetes. Mounjaro (tirzepatide) is not PBS-listed for any condition. The PBAC recommended it for type 2 diabetes, and in April 2026 Eli Lilly declined to proceed with the listing, saying the price the government was willing to pay was too low and the funding caps assigned it disproportionate risk. So every Australian on Mounjaro is paying a private script price today, whatever they are taking it for.
If you want either drug for weight management, you need a private prescription, which runs $300-500 per month depending on the dose and brand. Here is the full breakdown for 2026.
PBS Coverage at a Glance
| Ozempic (semaglutide) | Mounjaro (tirzepatide) | |
|---|---|---|
| PBS-subsidised | Type 2 diabetes | No, not PBS-listed for any condition |
| For weight loss | Private script only | Private script only |
| PBS copayment | Up to $25 (general) / $7.70 (concession) | Not applicable, no PBS listing |
| Private monthly cost | $300-450/month | $350-500/month |
| Prescribing | GP or specialist | GP or specialist |
PBS co-payment figures are current for 2026: the general co-payment fell from $31.60 to $25.00 on 1 January 2026 under the National Health Amendment (Cheaper Medicines) Act 2025, and the concessional rate stays at $7.70 until 2030. Private prices vary by pharmacy and dose.
Ozempic PBS Eligibility in Australia
Ozempic is PBS-subsidised for adults with type 2 diabetes when:
- You have a confirmed type 2 diabetes diagnosis.
- You have tried metformin first (unless contraindicated).
- Your HbA1c remains above target on existing therapy.
- Prescribed by a GP or endocrinologist.
Ozempic is not PBS-covered for weight loss or obesity management without type 2 diabetes. If your only indication is weight management, you need a private prescription.
The PBS-subsidised dose is typically 0.5mg or 1mg weekly. The 2mg dose for better glycaemic control may require authority prescription in some cases.
Mounjaro (Tirzepatide) PBS Status
Mounjaro has TGA approval in Australia for both type 2 diabetes and weight management. It has no PBS listing for either.
This is the part most Australian guidance still gets wrong, including, until this update, ours. The sequence was:
- The PBAC recommended tirzepatide for subsidy in adults with inadequately controlled type 2 diabetes.
- In April 2026, after a prolonged stand-off with the federal government over price, Eli Lilly declined to proceed with the PBS listing. It cited the price offered and funding caps it said placed disproportionate financial risk on the company.
- The PBS Medicine Status record for tirzepatide (document 1261) shows no listing steps commenced.
The practical effect: an estimated 450,000 Australians with type 2 diabetes who would have qualified do not get a subsidised script, and there is no PBS price for Mounjaro to compare against. Every Mounjaro prescription in Australia is a private one. Private monthly costs typically range $350-500 depending on dose and pharmacy.
Because a manufacturer withdrawal is a commercial decision rather than a scheduled review, there is no published date for a new attempt. Check pbs.gov.au/medicinestatus rather than trusting any predicted timeline, including one on this page.
Mounjaro is the first dual GIP/GLP-1 receptor agonist available in Australia. Clinical trials showed greater average weight loss than semaglutide at equivalent stages, which has made it popular for private weight management protocols.
Wegovy in Australia 2026
Wegovy (semaglutide 2.4mg) is TGA-approved in Australia for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition (verify current TGA indication at tga.gov.au). However, as of 2026 it remains on a limited supply list in Australia due to ongoing global manufacturing constraints.
PBS listing for Wegovy for obesity has not been finalised as of mid-2026 (verify current PBS status at pbs.gov.au). Most patients who qualify access it via private prescription while they wait for wider availability.
Ready to track your protocol?
- Smart reminders so you never miss a dose
- Progress tracking with photos and weight
- Medication level curves for every compound
Private Prescription Costs: What to Expect
If you do not have type 2 diabetes and want to use Ozempic or Mounjaro for weight management, you are paying out of pocket. Here is a realistic cost breakdown:
Ozempic (semaglutide) private script
- 0.25-0.5mg starter dose: ~$150-200/month
- 1mg maintenance dose: ~$300-380/month
- Sourced from a private GP or weight management clinic
Mounjaro (tirzepatide) private script
- 2.5mg starter dose: ~$200-280/month
- 5-10mg maintenance dose: ~$380-500/month
These prices vary by pharmacy and whether the clinic bundles the consultation into the cost. Most private weight management clinics in Australia charge a monthly fee that includes the consultation and prescription, typically $250-500/month all-in at the 1mg+ dose range.
How to Get a GLP-1 Prescription in Australia
For type 2 diabetes (PBS-covered)
- See your GP with a confirmed T2DM diagnosis and recent HbA1c result.
- Your GP confirms you have tried first-line options (typically metformin).
- Ozempic is prescribed on the PBS. Mounjaro cannot be, because it has no PBS listing.
- Fill at any pharmacy and pay the standard PBS co-payment, up to $25 general or $7.70 concessional.
For weight management (private prescription)
- Book a telehealth appointment or in-person visit with a GP or weight management clinic.
- Discuss your BMI, weight history, and any related conditions.
- If eligible, the doctor issues a private prescription.
- Fill at a pharmacy and pay full private price, no PBS subsidy.
Some telehealth platforms offer monthly subscriptions that include the consultation, prescription renewal, and support. This can simplify the process but tends to cost more upfront.
Can You Get Compounded GLP-1 in Australia?
Unlike the United States, Australia has much stricter rules around compounded GLP-1 medications. The TGA does not permit compounding of tirzepatide or semaglutide while brand-name equivalents are commercially available, with limited exceptions.
If you see a clinic or pharmacy offering compounded semaglutide or tirzepatide in Australia at a significantly lower price, check their authorisations carefully. Most legitimate Australian providers supply TGA-approved Ozempic or Mounjaro brand products, not compounded alternatives.
Tracking Your GLP-1 Protocol
Ozempic and Mounjaro are weekly injections with a titration schedule, where doses increase every 4 weeks. Tracking your injections, doses, side effects, and weight trends in one place makes it much easier to report back to your prescriber and see whether you are on the right titration timeline.
Regimen supports Ozempic, Mounjaro, and Wegovy tracking with dose reminders, titration calendars, blood level modelling, and Apple Health / Google Health Connect integration.
Frequently Asked Questions
Is Ozempic available in Australia in 2026?
Yes. Ozempic is available in Australia and is PBS-subsidised for type 2 diabetes. Supply constraints that affected Australia in 2023-2024 have largely resolved. For weight management without diabetes, you need a private prescription at full cost.
Is Mounjaro on the PBS in Australia?
No. Mounjaro is not PBS-listed in Australia for any condition, including type 2 diabetes. The PBAC recommended it for type 2 diabetes, but in April 2026 Eli Lilly declined to proceed with the listing over the price the government was willing to pay. Every Mounjaro script in Australia is a private one, typically $350-500 a month depending on dose.
When will Mounjaro be PBS-listed for obesity in Australia?
There is no date, and the obstacle is not the assessment. The PBAC already recommended tirzepatide for type 2 diabetes; the manufacturer walked away from that listing in April 2026 over price. Until Eli Lilly and the government reach terms, neither the diabetes nor the obesity indication has a path to the PBS, and no new application has a published timeline. Check the PBS Medicine Status page for tirzepatide rather than relying on a forecast.
Is Ozempic PBS-covered for weight loss?
No. Ozempic is PBS-covered only for type 2 diabetes management. For weight loss without a diabetes diagnosis, you need a private script. Wegovy (higher-dose semaglutide) is TGA-approved for obesity but not yet widely PBS-listed.
Is tirzepatide available in Australia?
Yes. Tirzepatide is available in Australia as Mounjaro and is TGA-approved for both type 2 diabetes and weight management. There is no PBS subsidy for either indication, so it is a private script at full price.
What is the cheapest way to get Ozempic in Australia?
If you have type 2 diabetes, the cheapest route is a PBS prescription for Ozempic, which costs up to $25 per month at the general rate or $7.70 with a concession card since the co-payment was reduced on 1 January 2026. If you do not have diabetes and want it for weight management, there is no PBS subsidy, and costs start around $150/month for the starter dose.
Track your Ozempic or Mounjaro dose, weight, and side effects with Regimen. Free for one compound.
Regimen is a tracking tool, not a medical service. We do not provide medical advice. Always consult your healthcare professional before starting, changing, or stopping any medication protocol.
Sources
- PBS Medicine Status, document 1261: tirzepatide’s PBS process and its current state.
- Lilly rejects Mounjaro T2D PBS listing and ABC News, 28 April 2026: the April 2026 withdrawal and the reasons given.
- PBS co-payments, Department of Health: the general co-payment cut to $25.00 on 1 January 2026 and the $7.70 concessional rate held to 2030.
PBS listings change. Confirm current status at pbs.gov.au before making treatment decisions.
